Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6062
- Development stage
- Phase 2
- Lead developer
- Suzhou Xinnuowei Pharmaceutical Technology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYS6062 is an investigational monoclonal antibody-drug conjugate (ADC) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), developed by CSPC Megalith Biopharmaceutical (a subsidiary of CSPC Pharmaceutical Group). The drug is designed to selectively bind to CEACAM5 on the surface of tumor cells, undergo receptor-mediated internalization via endocytosis, and release its cytotoxic payload intracellularly to induce cell death. SYS6062 is being evaluated in a Phase I/II clinical trial for the treatment of advanced solid tumors, including gastric cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on SYS6062.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6062.